May 11, 2012
Seikagaku Corporation and Kaken Pharmaceutical on May 10 announced that they have signed a basic agreement for marketing rights of the lumbar disc herniation treatment SI-6603 (condoliase), which is currently under development by Seikagaku. Kaken will acquire exclusive marketing rights...read more